Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations. 
X
Active Filter(s):
Details:
The launch of Fluphenazine Hydrochloride Tablets, USP, a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg, which is approved by the U.S. Food and Drug Administration (USFDA).
Lead Product(s): Fluphenazine
Therapeutic Area: Psychiatry/Psychology Product Name: Fluphenazine Hydrochloride-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2021
Details:
Fluphenazine hydrochloride Tablets are a generic version of the brand product, Prolixin. Company has launched Fluphenazine Hydrochloride Tablets, USP in four strengths, 1 mg, 2.5 mg, 5 mg, and 10 mg.
Lead Product(s): Fluphenazine
Therapeutic Area: Psychiatry/Psychology Product Name: Prolixin-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
